TPF: a rational choice for larynx preservation?
Calais
Gilles
G
Oncologie Radiothérapie, Centre Hospitalier Universitaire, Tours, France. calais@med.univ-tours.fr
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000077143:Docetaxel; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007825:Laryngectomy / Q000009:adverse effects / Q000523:psychology; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use
D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D005472:Fluorouracil